Introduction
============

Most patients with chronic obstructive pulmonary disease (COPD) are managed by general practitioners (GP). GPs face the challenge of providing effective health care for patients with a highly heterogeneous disease to reduce the great impact of COPD on patients' lives. An important part of the management includes an evaluation of disease severity and its implications for the choice of treatments. Interestingly, GPs do not base the evaluation of COPD patients on lung function only but consider other prognostically important markers such as history of exacerbations or dyspnea.[@b1-clep-3-273],[@b2-clep-3-273] Such practice is supported by evidence that shows that lung function incompletely reflects patients' health state and is, in fact, associated only weakly with prognosis.[@b2-clep-3-273]--[@b6-clep-3-273] There is increasing agreement among experts that characterizing patients should be based on combinations of prognostically important characteristics such as frequency of exacerbations, exercise capacity, and dyspnea that better reflect the multifaceted nature of COPD than a single parameter.[@b7-clep-3-273]

An attractive approach for combining patient characteristics are scores such as the BODE (body mass index, obstruction, dyspnea, and exercise capacity), ADO (age, dyspnea, and obstruction) or DOSE (dyspnea, obstruction, smoking status, and exacerbation frequency) indices.[@b1-clep-3-273],[@b3-clep-3-273],[@b8-clep-3-273] Such scores can be used to assess the risk for premature mortality or exacerbations and may guide therapeutic management. Unfortunately, there seems to be low awareness for these indices in primary care,[@b9-clep-3-273] which may be due to the unavailability of some components such as the 6-minute walk distance or the lack of validation in primary care cohorts. The ADO and DOSE indices overcome some of these limitations by including only parameters easily available in primary care.[@b1-clep-3-273],[@b8-clep-3-273] However, GPs may also be interested in the prediction of the clinical course of their patients in terms of measures of symptoms and health-related quality of life. Therefore, disease severity indices for COPD patients should be developed or at least validated in primary care populations because they may reflect a COPD population that is different from many COPD cohorts that are mainly recruited in secondary and tertiary care centers. The International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts (ICE COLD ERIC) study was designed to develop and validate such practical COPD severity indices in primary care patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages II--IV.[@b10-clep-3-273] This paper describes baseline characteristics and provides a detailed characterization of the ICE COLD ERIC cohorts.

Methods and design
==================

ICE COLD ERIC is an international study in which two prospective cohort studies with primary care COPD patients (GOLD stages II--IV) from Switzerland and The Netherlands are linked. All included patients have provided written informed consent. The study has been approved of by all local ethics committees and is registered on ClinicalTrials. gov (NCT00706602).

Population
----------

Included patients are ≥40 years of age with COPD in GOLD stages II--IV who were able to complete the baseline assessment and had been free of exacerbation for at least 4 weeks. Exclusion criteria were a life expectancy of ≤12 months, dementia, psychosis or other psychiatric morbidity that would invalidate assessment of patient-reported parameters, and inability to complete the baseline assessment due to language difficulties. Patients were included between April 2008 and April 2009.

A single protocol for both countries was designed for the baseline assessment and follow-up assessments. To ensure comparability, we developed and pilot tested case report forms and instructions for testing. Investigators meet twice a year and have frequent telephone and email contact to ensure that the assessments remain similar in both countries. More details on the study protocol were reported elsewhere.[@b10-clep-3-273]

Study design and methods
------------------------

The baseline assessment[@b10-clep-3-273] consisted of lung function measurement (forced expiratory volume in 1 second \[FEV~1~\], forced vital capacity \[FVC\], and inspiratory reserve volume \[IRV\]) after bronchodilation with two puffs of 100 μg salbutamol through a spacer, a detailed patient history with general information (date of birth, sex, living situation, occupation, and education) and COPD-specific information (year of diagnosis, smoking history, current smoking, exposure to smoke at home, exacerbations, chronic cough, and phlegm), detailed registration of comorbidities, and use of drugs and any nondrug treatments for COPD and other diseases (self-reported). It also included measurement of BMI (as calculated by height/weight[@b2-clep-3-273]). All patients completed several questionnaires. To assess dyspnea, they completed the Medical Research Council[@b11-clep-3-273] (MRC) dyspnea scale with a score of zero to four where zero is "no or little dyspnea associated with heavy physical activity" and four is "too breathless to leave the house or breathless when (un) dressing." For COPD-specific health-related quality of life, the Chronic Respiratory Questionnaire (CRQ) was used.[@b12-clep-3-273]--[@b14-clep-3-273] The CRQ provides scores in four different domains ( dyspnea, fatigue, emotional, and mastery) each on a scale of one to seven, where one is the worst score indicating very poor health-related quality of life and seven the best. Patients scored their health on the Feeling Thermometer,[@b15-clep-3-273]--[@b17-clep-3-273] a scale of zero (very bad) to 100 (very good) and they answered three questions for measuring self-efficacy, the patient's belief in his or her skills to manage the illness. A short COPD-specific instrument was used to measure the patient's self-efficacy. It contained three questions for coping with COPD, dyspnea, and the use of pulmonary drugs, respectively, on a five-point scale from one (not confident) to five (very confident). Finally, the hospital anxiety and depression scale[@b18-clep-3-273],[@b19-clep-3-273] (HADS) was used to provide scores for depression and anxiety. Scores above eight indicate that a depression and/or anxiety disorder is likely to be present. Two tests were performed to measure exercise capacity, the sit-to-stand test and the handgrip strength test. During the sit-to-stand test patients hold their hands on their hips and they complete the sitting and standing positions on a chair without arm rests for 1 minute as correctly and as fully as possible without using the arms for support.[@b20-clep-3-273] The handgrip test is used to assess grip strength of both hands with the Jamar^®^ Hydraulic Hand Dynamometer (JA Preston Corporation, Jackson, MI).[@b21-clep-3-273] A blood sample was taken from each patient to measure creatinine, bilirubin, alanine-aminotransferase, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, C-reactive protein, carboxyhemoglobin, and leukocytes. A differential blood count was performed and DNA was extracted and stored at −80°C. Finally, for every patient, ADO and DOSE indices were calculated.[@b1-clep-3-273],[@b8-clep-3-273] The ADO index estimates the 3-year mortality risk and the DOSE index estimates health status. Of note, the ability of the ADO and DOSE indices to predict mortality, exacerbations, and health status in these populations will be reported when follow-up assessments are completed.

Statistical analysis
--------------------

Summary statistics were calculated for all variables. Percentages and absolute numbers are used to describe dichotomous and categorical variables. Median, fifth percentile, and 95th percentile are used to describe continuous variables. The fifth percentile means that only 5% of the observed values is lower than that value and the 95th percentile means that 95% is lower than that value (and only 5% higher). Data were analyzed using Stata software (v 10.1; StataCorp, College Station, TX).

Results
=======

[Table 1](#t1-clep-3-273){ref-type="table"} summarizes general and COPD-specific patient characteristics. Male/female ratio was 50/50 for the Dutch and 68/32 for the Swiss cohort. The median age was 66 years in the Dutch and 67 years in the Swiss cohort. Half of the patients in both cohorts had a diagnosis of COPD for less than 5 years and 19% of the Swiss and 9% of the Dutch patients had this diagnosis for less than 1 year. The median number of pack years was 37 for the Dutch and 45 for the Swiss cohort. The percentage of smokers vs former smokers was 40% vs 53% for the Dutch cohort and 35% vs 58% for the Swiss cohort. Four percent of the Dutch cohort reported they had never smoked in their life vs 6% of the Swiss cohort. Around 33% of patients had one or more exacerbations in the previous year. The median MRC score was 2.5 for the Dutch and one for the Swiss cohort; 39% of the Dutch cohort had the maximum (worst) MRC score vs 0% of the Swiss cohort. Median, fifth, and 95th percentiles of MRC scores for each of the three GOLD categories were also calculated.

[Figure 1](#f1-clep-3-273){ref-type="fig"} shows the frequencies of comorbidities and of their simultaneous presence. These Venn diagrams show comorbidities and multimorbidities for the Dutch cohort, the Swiss cohort, and the total cohort. The diagrams are next to each other, the sharing of the cells is similar, and the percentages in the cells represent the (overlap of) comorbidity, which makes it easy to compare the cohorts with each other. Group A (black) represents cardiovascular disease consisting of coronary artery disease, chronic heart failure, and cerebrovascular disease. Group B (red) represents type 1 and type 2 diabetes mellitus. Group C (blue) represents musculoskeletal disease, mainly osteoarthritis and rheumatoid arthritis. Group D (green) represents other comorbidities such as asthma, malignancies, and infectious disease.

As shown in [Table 2](#t2-clep-3-273){ref-type="table"}, 88% of the Dutch cohort used pulmonary drugs vs 76% of the Swiss cohort with the highest percentages for inhaled corticosteroids and long-acting beta-agonists. Around 14% used antidiabetic drugs, usually oral antidiabetics, and 66% had at least one cardiovascular drug, usually anticlotting. Around 40% in both cohorts had nondrug interventions, mainly physical exercise. Around 8% in the Dutch cohort and 10% in the Swiss cohort had pulmonary rehabilitation.

In all CRQ domains Swiss patients had higher scores than Dutch patients ([Table 3](#t3-clep-3-273){ref-type="table"}). HADS anxiety scores were quite similar whereas the HADS depression scores indicated more symptoms of depression in the Dutch cohort compared to the Swiss cohort. As expected, the CRQ dyspnea domain patients in higher GOLD categories had more dyspnea. For the other CRQ domains, Feeling Thermometer and HADS, the differences between patients in different GOLD categories were small.

In both exercise capacity tests the Swiss cohort showed higher exercise capacity than the Dutch cohort ([Table 4](#t4-clep-3-273){ref-type="table"}). For the sit-to-stand test, differences were small between GOLD categories and no difference between GOLD categories for the hand grip test results was observed. The median score on the ADO index was five for the Dutch cohort and three for the Swiss, meaning that the Dutch had a higher risk of 3-year mortality than the Swiss, 16.3% (fifth to 95th percentile: 7.9%--26.5%) vs 11.5% (fifth to 95th percentile: 7.9%--19.3%). The median score on the DOSE-index was two for the Dutch cohort and one for the Swiss cohort, suggesting that Swiss patients had a better health status (as measured by the CCQ total score) than the Dutch.

The median values of FEV~1~ percentage (FEV~1~%) of predicted were 58% and 59% and FEV~1~/FVC ratio were 0.52 and 0.57 for the Dutch and the Swiss cohort, respectively ([Table 5](#t5-clep-3-273){ref-type="table"}). The percentage of A-quality (best) for lung function measurement was 62% for the Dutch and 38% for the Swiss cohort. The GOLD classification was as follows: in the Dutch cohort 67% was classified as GOLD stage II, 25% as GOLD stage III, and 9% as GOLD stage IV. In the Swiss cohort 63% was classified as GOLD stage II, 27% as GOLD stage III, and 11% as GOLD stage IV. Laboratory results are shown in [Table 6](#t6-clep-3-273){ref-type="table"}.

Discussion
==========

The analysis of these cohorts indicates that the impact of COPD was quite different in the Dutch and the Swiss cohort although lung function and the prevalence of comorbidity and multimorbidity were quite similar. Swiss patients reported higher scores on all CRQ domains than Dutch patients and for all domains these differences were 0.5 or higher (minimal important difference = 0.5),[@b14-clep-3-273] indicating that the Swiss patients reported better COPD-specific health-related quality of life. On classifying patients according to GOLD category, these differences became even larger. This is also reflected in MRC scores where Dutch patients reported more dyspnea than Swiss patients. In both exercise tests, the Swiss patients showed higher exercise capacity than the Dutch patients. And, the Swiss cohort had a lower 3-year risk of mortality than the Dutch cohort, 11.5% vs 16.3%.

Approximately 50% of all patients received their COPD diagnosis less than 5 years ago. Of these, 9% of the Dutch patients and 19% of the Swiss had their COPD diagnosis for less than 1 year and were probably diagnosed as a result of their participation in this study. The fact that more Swiss patients were diagnosed within this study may be explained by differences in the identification and recruitment process between Switzerland and The Netherlands.[@b10-clep-3-273] In Switzerland, GPs known to have an active interest in research activities were involved and, through them, more GPs potentially willing to participate were identified (snowball approach). Participating GPs identified potentially eligible patients through electronic or paper-based patient charts. For electronic patient charts GPs searched with the key terms "COPD," "chronic bronchitis," "emphysema," "asthma," and a combination of "smoking," "≥40 years of age," and "male" to identify patients with COPD. Paper-based patient charts were screened by hand. Potentially eligible patients were informed about the study and invited by telephone for eligibility testing. In The Netherlands, COPD patients were identified from primary health care centers registered in the GP research network of the Department of General Practice of the University of Amsterdam in Almere and Amsterdam. These patients received study information and an invitation letter from their GP. Patients who were not interested in participating or who did not wish to receive a phone call returned a reply card indicating as much. All patients who did not respond via the reply card were invited by telephone for eligibility testing.

In terms of the lung function measurement that was performed at study entry, the quality was better in The Netherlands than in Switzerland despite identical devices and a single protocol. It looks as if the number of measurement repetitions was lower in Switzerland thereby lowering the probability that three or more measurements were of high enough quality for an A or B rating to occur. Site investigators in Switzerland generally stopped repeating the measurements when a diagnosis of COPD was confirmed whereas in The Netherlands the investigators aimed for quality grades A or B by having more repeated measurements to obtain a more reliable measurement. Potential differences in measurement error are currently being investigated by analyzing the exact measurement variability between the countries using intraclass correlations instead of ABCD ratings.

With regard to representativeness, some basic characteristics (sex, age, pack years, FEV~1~% of predicted, and GOLD classification) of the ICE COLD ERIC cohort have been compared with two other COPD cohorts from the literature (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints \[ECLIPSE\] and Investigating New Standards for Prophylaxis In Reducing Exacerbations \[INSPIRE\]).[@b22-clep-3-273],[@b23-clep-3-273] No differences were seen in age and pack years. In both the ECLIPSE and INSPIRE cohort, the percentage of males was larger (65% and 80%, respectively), the FEV~1~% of predicted was lower (48% and 39%, respectively) and the prevalence of GOLD stage III (42% and 82%, respectively) and GOLD stage IV (14% and 15%, respectively) was higher. Overall, the ECLIPSE and INSPIRE study included more severe COPD patients than the ICE COLD ERIC study, which can be explained by differences in setting and inclusion criteria.[@b22-clep-3-273],[@b23-clep-3-273] The ICE COLD ERIC cohort is a representative cohort for COPD patients in primary care and may be used for purposes of worldwide collaboration on primary care data on COPD.[@b24-clep-3-273]

One strength of the ICE COLD ERIC study is that it is an international prospective study with two cohorts from different countries linked by a single study protocol. Another strength of the study is that these cohorts were recruited in primary care and that the data collection is elaborate, especially with regard to comorbidity and drug use. Although the majority of COPD patients are managed in primary care, many previous cohorts were recruited in hospital settings or COPD clinics, which may reflect a COPD population with different characteristics. Also, comorbidities are often not properly reported in cohort studies. Patients from primary care represent a wide range of COPD severity and may have several coexisting diseases, which is also reflected in multifaceted therapies. The ICE COLD ERIC study cohorts will have an important contribution to (prognostic) research on COPD and characterizing COPD patients. The latter may be clinically important not only for its prognostic value but also for its therapeutic value, for a better understanding of the pathophysiology of COPD, and for genetic research in COPD. For example, responses to therapies such as the use of long-term oxygen or lung volume reduction surgery may differ between different (sub)types of patients.[@b25-clep-3-273]--[@b28-clep-3-273]

The rich variability within the ICE COLD ERIC cohorts offers many opportunities to learn more about the clinical course of COPD in a primary care population that represents the vast majority of COPD patients. The main purpose of the study is development and validation of practical prognostic COPD risk indices. Important risk predictors will be identified for dimensions of health-related quality of life, exacerbation risk, and mortality. For example, health-related quality of life was measured by the CRQ, which provides scores for four different domains. According to the score per domain, physicians may select treatment options for individual patients to improve their (domain-specific) health-related quality of life. Treatment decisions should be based on the needs of the individual patient, probably resulting in fewer unnecessary treatment prescriptions (for example, the widely prescribed inhaled corticosteroids in patients with mild disease), fewer exacerbations, and a better COPD-specific health-related quality of life. COPD management may also become more cost-effective by tailoring treatment decisions better to the needs of the individual patient.

In a second step, evidence-based treatment effects mainly from randomized trials and meta-analyses will be incorporated, such that the instrument may guide physicians in selecting treatment based on the individual patients' prognoses. Ways to incorporate treatment advices into the prediction indices may be challenging and are currently being explored by this team. For example, a mortality risk of 30% for a COPD patient may be reduced to 24% by a certain treatment if the relative risk reduction is 0.8. The absolute risk reduction is 6%. For another COPD patient with a mortality risk of 3%, that same treatment with a relative risk reduction of 0.8 will reduce the mortality risk to 2.4%, an absolute risk reduction of 0.6%. Adding cost considerations may lead to a recommendation to treat the former and not the latter patient. This is an example of risk-stratified treatment choices.

In summary, COPD patients in ICE COLD ERIC represent a wide range of disease severity and the prevalence of multimorbidity is high. These data show that the impact of COPD can be substantially different across patients even if lung function and the prevalence of comorbidities are quite similar. The rich variation in these prospective cohorts offers good opportunities to learn more about the clinical course of COPD in a primary care population representing the vast majority of COPD patients.
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###### 

Patient characteristics of 260 Dutch and 151 Swiss chronic obstructive pulmonary disease patients (total cohort N = 411) enrolled in the International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts prospective cohort study

  --------------------------------------------------------------------------------------------
                                      Dutch cohort\      Swiss cohort\      Total cohort\
                                      n, (%)             n, (%)             n, (%)
  ----------------------------------- ------------------ ------------------ ------------------
  Sex                                                                       

   Male                               130 (50.0)         103 (68.2)         233 (56.7)

   Female                             130 (50.0)         48 (31.8)          178 (43.3)

  Age                                                                       

   p5, p50, p95                       51, 66, 83         52, 67, 81         51, 66, 82

  BMI                                                                       

   p5, p50, p95                       18.8, 25.5, 35.8   19.8, 25.2, 35.1   19.5, 25.4, 35.1

  Living situation                                                          

   Alone                              103 (39.6)         46 (30.5)          149 (36.3)

   With partner                       117 (45.0)         95 (62.9)          212 (51.6)

   With children                      12 (4.6)           3 (2.0)            15 (3.6)

   With partner and children          28 (10.8)          5 (3.3)            33 (8.0)

   Unknown                            0 (0.0)            2 (1.3)            2 (0.5)

  Profession                                                                

   Working                            53 (20.4)          36 (23.8)          89 (21.7)

   House wife                         21 (8.1)           1 (0.7)            22 (5.4)

   Retired                            132 (50.8)         106 (70.2)         238 (57.9)

   Disabled                           53 (20.4)          8 (5.3)            61 (14.8)

   Unemployed                         1 (0.4)            0 (0.0)            1 (0.2)

  Highest education                                                         

   Primary school                     57 (21.9)          21 (13.9)          78 (19.0)

   Secondary school                   115 (44.2)         105 (69.5)         220 (53.5)

   Intermediate vocational            53 (20.4)          15 (9.9)           68 (16.5)

   Higher vocational/university       34 (13.1)          6 (4.0)            40 (9.7)

   Unknown                            1 (0.4)            4 (2.6)            5 (1.2)

  Diagnosis of COPD since                                                   

   \<1 year                           23 (8.8)           29 (19.2)          52 (12.6)

   1--5 years                         102 (39.2)         45 (29.8)          147 (35.8)

   5--10 years                        48 (18.5)          27 (17.9)          75 (18.2)

   \>10 years                         65 (25.0)          42 (27.8)          107 (26.0)

   Unknown                            22 (8.5)           8 (5.3)            30 (7.3)

  Pack years                                                                

   p5, p50, p95                       1, 37, 82          0, 45, 110         1, 40, 90

  Smoking habits                                                            

   Nonsmoker                          10 (3.9)           9 (6.0)            19 (4.6)

   Former smoker                      137 (52.7)         87 (57.6)          224 (54.5)

   Current smoker                     104 (40.0)         53 (35.1)          157 (38.2)

   Cigarettes per day                                                       

    p5, p50, p95                      3, 15, 40          3, 20, 50          3, 15, 40

   Passive smoker                     11 (4.2)           28 (18.5)          39 (9.5)

   Cigar smoker                       8 (3.1)            4 (2.7)            12 (2.9)

   Pipe smoker                        4 (1.5)            6 (4.0)            10 (2.4)

  Exacerbations treated at home                                             

   0                                  171 (65.8)         102 (67.5)         273 (66.4)

   1--2                               75 (28.8)          47 (31.1)          122 (29.7)

   \>2                                14 (5.4)           1 (0.7)            15 (3.6)

   Unknown                            0 (0.0)            1 (0.7)            1 (0.2)

  Exacerbations treated in hospital                                         

   0                                  248 (95.4)         137 (90.7)         385 (93.7)

   1--2                               11 (4.2)           12 (7.9)           23 (5.6)

   \>2                                1 (0.4)            1 (0.7)            2 (0.5)

   Unknown                            1 (0.0)            1 (0.7)            1 (0.2)

  MRC score                                                                 

   p5, p50, p95                       0, 2.5, 4          0, 1, 3            0, 1, 4

   GOLD II                            0, 1, 4            0, 1, 2            0, 1, 4

   GOLD III                           1, 4, 4            0, 1, 3            1, 2, 4

   GOLD IV                            1, 4, 4            1, 2, 3            1, 3, 4

   0                                  37 (14.2)          34 (22.5)          71 (17.3)

   1                                  77 (29.6)          78 (51.7)          155 (37.7)

   2                                  16 (6.2)           25 (16.6)          41 (10.0)

   3                                  28 (10.8)          14 (9.3)           42 (10.2)

   4                                  102 (39.2)         0 (0.0)            102 (24.8)

  Chronic cough                                                             

   Yes                                122 (46.9)         79 (52.3)          201 (48.9)

   No                                 138 (53.1)         72 (47.7)          210 (51.1)

  Chronic phlegm                                                            

   Yes                                120 (46.2)         79 (52.3)          199 (48.4)

   No                                 139 (53.5)         70 (46.4)          209 (50.9)

   Unknown                            1 (0.4)            2 (1.3)            3 (0.7)
  --------------------------------------------------------------------------------------------

**Notes:** MRC score is divided into five categories: 0 = breathless with strenuous exercise, 1 = breathless when hurrying or walking up a slight hill, 2 = walks slower than other people of the same age because of breathlessness or has to stop for breath when walking at own pace, 3 = has to stop for breath after walking 100 yards or after a few minutes, 4 = too breathless to leave the house or breathless while (un)dressing. Numbers in GOLD stage II, III, and IV are 174, 64, and 22 for Dutch, 95, 40, and 16 for Swiss, and 269, 104, and 38 for total cohort.

**Abbreviations:** BMI, body mass index; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; MRC, medical research council; p5, fifth percentile, p50, median, p95, 95th percentile.

###### 

Drug and nondrug interventions of 260 Dutch and 151 Swiss chronic obstructive pulmonary disease patients (total cohort N = 411) enrolled in the International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts prospective cohort study

  --------------------------------------------------------------------------------------------
                                               Dutch cohort\   Swiss cohort\   Total cohort\
                                               n, (%)          n, (%)          n, (%)
  -------------------------------------------- --------------- --------------- ---------------
  No drugs at all                              6 (2.3)         6 (4.0)         12 (2.9)

  Pulmonary drugs                              229 (88.1)      115 (76.2)      344 (83.7)

   Ipratropium                                 41 (17.9)       12 (10.4)       53 (15.4)

   Local steroids                              164 (71.6)      74 (64.3)       238 (69.2)

   Long-acting beta-agonists                   169 (73.8)      76 (66.1)       245 (71.2)

   Short acting beta-agonists                  80 (34.9)       39 (33.9)       119 (34.6)

   Tiotropium                                  111 (48.5)      45 (39.1)       156 (45.3)

   Systemic steroids                           11 (4.8)        10 (8.7)        21 (6.1)

   Parasympaticolytics                         2 (0.9)         1 (0.9)         3 (0.9)

  Cardiovascular drugs                         172 (66.2)      101 (66.9)      273 (66.4)

   ACE inhibitors                              79 (45.9)       37 (36.6)       116 (42.5)

   Anticlotting                                93 (54.1)       65 (64.4)       158 (57.9)

   Angiotensin-2-receptor inhibitors           19 (11.0)       23 (22.8)       42 (15.4)

   Beta-antagonists                            57 (33.1)       37 (36.6)       94 (34.4)

   Calcium-antagonists                         34 (19.8)       19 (18.8)       53 (19.4)

   Diuretics                                   77 (44.8)       48 (47.5)       125 (45.8)

   Statins                                     86 (50.0)       34 (33.7)       120 (44.0)

  Antidiabetic drugs                           38 (14.6)       21 (13.9)       59 (14.4)

   Oral antidiabetics                          25 (65.8)       11 (52.4)       36 (61.0)

   Insulin                                     13 (34.2)       9 (42.9)        22 (37.3)

  Analgesia                                    38 (14.6)       30 (19.9)       68 (16.6)

   NSAIDs                                      14 (36.8)       11 (36.7)       25 (36.8)

   Other                                       21 (55.3)       14 (46.7)       35 (51.5)

  Psychiatric drugs                            59 (22.7)       30 (19.9)       89 (21.7)

   Antidepressives                             25 (42.4)       17 (56.7)       42 (47.2)

   Anxiolytics/sedative/sleep                  42 (71.2)       15 (50.0)       57 (64.0)

  Other drugs                                  165 (63.5)      73 (48.3)       238 (57.9)

  Nondrug therapies                            100 (38.5)      60 (39.7)       160 (38.9)

   Long-term oxygen treatment                  7 (7.0)         5 (8.3)         12 (7.5)

   Oxygen during exertion                      3 (3.0)         1 (1.7)         4 (2.5)

   Fitness training at home                    15 (15.0)       37 (61.7)       52 (32.5)

   Fitness training in a program               37 (37.0)       23 (38.3)       60 (37.5)

   Lung volume reduction surgery               0 (0.0)         2 (3.3)         2 (1.3)

   Pulmonary rehabilitation in the last year   1 (1.0)         6 (10.0)        7 (4.4)

   Pulmonary rehabilitation \>1 year ago       7 (7.0)         0 (0.0)         7 (4.4)

   Devices                                     62 (23.8)       2 (3.3)         64 (40.0)

   Other                                       4 (4.0)         7 (11.7)        11 (6.9)
  --------------------------------------------------------------------------------------------

**Abbreviations:** ACE, angiotensin-converting enzyme; NSAIDs, nonsteroidal antiinflammatory drugs.

###### 

Patient-reported outcomes of 260 Dutch and 151 Swiss chronic obstructive pulmonary disease patients (total cohort N = 411) enrolled in the International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts prospective cohort study

                                       Dutch cohort    Swiss cohort    Total cohort
  --------------------- -------------- --------------- --------------- ---------------
  CRQ                                                                  
   Dyspnea              p5, p50, p95   2.0, 4.5, 7.0   2.8, 5.0, 7.0   2.2, 4.8, 7.0
    GOLD II                            2.2, 5.2, 7.0   3.2, 5.5, 7.0   2.5, 5.3, 7.0
    GOLD III                           2.0, 3.7, 6.8   3.0, 4.4, 6.7   2.2, 4.0, 6.8
    GOLD IV                            1.0, 3.1, 7.0   2.2, 4.4, 6.4   1.0, 3.2, 7.0
   Fatigue              p5, p50, p95   1.8, 4.0, 6.5   2.5, 5.3, 6.5   2.0, 4.5, 6.5
    GOLD II                            1.8, 4.3, 6.5   2.5, 5.3, 6.5   2.0, 4.5, 6.5
    GOLD III                           1.5, 4.0, 6.5   2.4, 4.8, 6.0   2.0, 4.3, 6.0
    GOLD IV                            1.5, 3.8, 5.8   2.5, 5.4, 6.5   1.5, 4.0, 6.3
   Emotional            p5, p50, p95   2.7, 5.1, 6.9   3.0, 5.6, 6.7   2.7, 5.4, 6.7
    GOLD II                            2.7, 5.1, 6.7   2.9, 5.6, 6.6   2.7, 5.4, 6.7
    GOLD III                           3.1, 5.3, 6.9   3.5, 5.5, 6.5   3.3, 5.4, 6.9
    GOLD IV                            2.7, 5.1, 6.9   2.6, 5.8, 7.0   2.6, 5.5, 6.9
   Mastery              p5, p50, p95   3.3, 5.5, 7.0   3.5, 6.0, 7.0   3.3, 5.8, 7.0
    GOLD II                            3.0, 5.8, 7.0   3.5, 6.0, 7.0   3.3, 5.8, 7.0
    GOLD III                           3.8, 5.5, 7.0   3.3, 5.6, 6.9   3.8, 5.5, 7.0
    GOLD IV                            3.3, 5.5, 6.8   2.8, 6.1, 7.0   3.0, 5.8, 7.0
  HADS                                                                 
   Depression           p5, p50, p95   1, 5, 12        1, 4, 10        1, 5, 11
    GOLD II                            1, 5, 11        0, 4, 10        0, 5, 11
    GOLD III                           1, 5, 12        1, 4, 10        1, 4, 11
    GOLD IV                            2, 6, 12        1, 4, 11        1, 6, 12
    Scores above 8      n (%)          58 (22.5)       13 (8.7)        71 (17.4)
   Anxiety              p5, p50, p95   0, 4, 13        0, 3, 12        0, 4, 13
    GOLD II                            0, 5, 14        0, 3, 12        0, 4, 13
    GOLD III                           0, 4, 12        1, 3, 9         0, 3, 10
    GOLD IV                            0, 5, 13        0, 2, 15        0, 5, 14
    Scores above 8      n (%)          53 (20.5)       13 (8.8)        66 (16.3)
  Self efficacy                                                        
   Illness              p5, p50, p95   2, 4, 5         2, 4, 5         2, 4, 5
    GOLD II                            2, 4, 5         3, 4, 5         3, 4, 5
    GOLD III                           2, 4, 5         1, 4, 5         2, 4, 5
    GOLD IV                            2, 4, 5         1, 5, 5         2, 4, 5
   Dyspnea              p5, p50, p95   1, 4, 5         2, 4, 5         1, 4, 5
    GOLD II                            1, 4, 5         2, 4, 5         2, 4, 5
    GOLD III                           2, 4, 5         1, 4, 5         2, 4, 5
    GOLD IV                            1, 3, 5         2, 4, 5         1, 3, 5
   Medication           p5, p50, p95   2, 5, 5         1, 5, 5         1, 5, 5
    GOLD II                            2, 5, 5         1, 4, 5         1, 5, 5
    GOLD III                           4, 5, 5         1, 5, 5         2, 5, 5
    GOLD IV                            2, 5, 5         1, 5, 5         2, 5, 5
  Feeling thermometer   p5, p50, p95   44, 70, 93      40, 75, 95      43, 70, 95
    GOLD II                            45, 70, 95      50, 75, 95      45, 70, 95
    GOLD III                           47, 68, 80      40, 65, 85      47, 65, 85
    GOLD IV                            40, 60, 70      4, 63, 90       7, 60, 88

**Notes:** CRQ on a scale of one (worst) to seven (best). HADS score \> 8 means anxiety/depression likely. Self efficacy questions on a scale of one (worst) to five (best). Feeling thermometer on a scale of zero (very bad health) to 100 (very good health). Numbers in GOLD stage II, III, and IV are 174, 64, and 22 for Dutch, 95, 40, and 16 for Swiss, and 269, 104, and 38 for total cohort.

**Abbreviations:** CRQ, Chronic Respiratory Questionnaire; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HADS, hospital anxiety and depression scale; p5, fifth percentile; p50, median; p95, 95th percentile.

###### 

Exercise capacity and age, dyspnea, and obstruction index among 260 Dutch and 151 Swiss chronic obstructive pulmonary disease patients (total cohort N = 411) enrolled in the International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts prospective cohort study

                                                Dutch cohort   Swiss cohort   Total cohort
  ------------------------------ -------------- -------------- -------------- --------------
  Sit-to-stand test (x/minute)   p5, p50, p95   0, 14, 24      11, 22, 40     0, 17, 35
    GOLD II                                     0, 15, 25      12, 23, 40     0, 18, 35
    GOLD III                                    0, 15, 23      0, 20, 42      0, 17, 39
    GOLD IV                                     0, 10, 17      13, 18, 30     0, 13, 26
  Hand grip test                                                              
   Right hand (kg)               p5, p50, p95   16, 30, 52     20, 40, 58     18, 32, 56
    GOLD II                                     15, 30, 54     18, 40, 58     17, 32, 56
    GOLD III                                    18, 32, 49     21, 40, 66     18, 34, 56
    GOLD IV                                     16, 30, 50     20, 41, 54     16, 36, 53
   Left hand (kg)                p5, p50, p95   12, 28, 50     20, 36, 54     14, 32, 52
    GOLD II                                     12, 28, 50     20, 36, 56     14, 32, 52
    GOLD III                                    14, 30, 50     18, 35, 54     16, 32, 53
    GOLD IV                                     14, 27, 48     16, 37, 50     14, 29, 50
  ADO index                      p5, p50, p95   1, 5, 8        1, 3, 6        1, 4, 7
  DOSE index                     p5, p50, p95   0, 2, 6        0, 1, 4        0, 1, 5

**Notes:** ADO index is an estimation of 3-year risk of mortality. A score of five indicates a 3-year risk of mortality of 16.3%, score of 3 indicates a 3-year risk of mortality of 11.5%, and score of four indicates a 3-year risk of mortality of 13.7%. DOSE index is an estimation of health status as measured by the CCQ total score. Numbers in GOLD stage II, III, and IV are 174, 64, and 22 for Dutch, 95, 40, and 16 for Swiss, and 269, 104, and 38 for total cohort.

**Abbreviations:** ADO, age, dyspnea and obstruction; DOSE, dyspnea, obstruction, smoking status, and exacerbation frequency; GOLD, Global Initiative for Chronic Obstructive Lung Disease; p5, fifth percentile; p50, median; p95, 95th percentile.

###### 

Lung function among 260 Dutch and 151 Swiss chronic obstructive pulmonary disease patients (total cohort N = 411) enrolled in the International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts prospective cohort study

  -----------------------------------------------------------------------------------------------------
                                               Dutch cohort       Swiss cohort       Total cohort
  ----------------------------- -------------- ------------------ ------------------ ------------------
  FEV~1~ (l)                    p5, p50, p95   0.64, 1.44, 2.56   0.63, 1.50, 2.47   0.63, 1.45, 2.56

  FEV~1~, % of predicted        p5, p50, p95   26, 58, 77         24, 59, 79         25, 59, 78

  FVC (l)                       p5, p50, p95   1.66, 2.84, 4.55   1.43, 2.84, 4.42   1.56, 2.84, 4.48

  FVC, % of predicted           p5, p50, p95   57, 90, 118        53, 84, 117        55, 88, 118

  FEV~1~/FVC                    p5, p50, p95   0.29, 0.52, 0.67   0.31, 0.57, 0.70   0.29, 0.53, 0.68

  Inspiratory capacity          p5, p50, p95   0.95, 2.13, 3.68   1.32, 2.39, 3.63   1.13, 2.23, 3.63

  Quality of measurement\       A              162 (62.3)         58 (38.4)          220 (53.5)
  n (%)                                                                              

                                B              64 (24.6)          22 (14.6)          86 (20.9)

                                C              34 (13.1)          36 (23.8)          70 (17.0)

                                D              0 (0.0)            34 (22.5)          34 (8.3)

                                Less than D    0 (0.0)            1 (0.7)            1 (0.2)

  GOLD II (50 ≤ FEV% \< 80)\                   174 (66.9)         95 (62.9)          269 (65.5)
  n (%)                                                                              

  GOLD III (30 ≤ FEV% \< 50)\                  64 (24.6)          40 (26.5)          104 (25.3)
  n (%)                                                                              

  GOLD IV (FEV~1~ % \< 30)\                    22 (8.5)           16 (10.6)          38 (9.3)
  n (%)                                                                              
  -----------------------------------------------------------------------------------------------------

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; p5, fifth percentile; p50, median; p95, 95th percentile.

###### 

Laboratory results among 260 Dutch and 151 Swiss chronic obstructive pulmonary disease patients (total cohort N = 411) enrolled in the International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts prospective cohort study

                                              Dutch cohort     Swiss cohort     Total cohort
  ---------------------------- -------------- ---------------- ---------------- ----------------
  Creatinine (μmol/L)          p5, p50, p95   48, 72, 126      63, 88, 142      50, 77, 132
  Bilirubin (μmol/L)           p5, p50, p95   4, 8, 15         4, 8, 21         4, 8, 16
  ALAT (U/L)                   p5, p50, p95   11, 21, 56       12, 24, 52       12, 22, 52
  Total cholesterol (mmol/L)   p5, p50, p95   3.4, 5.3, 7.5    3.9, 5.8, 7.9    3.5, 5.5, 7.7
  HDL cholesterol (mmol/L)     p5, p50, p95   0.9, 1.5, 2.3    0.9, 1.5, 2.4    0.9, 1.5, 2.3
  LDL cholesterol (mmol/L)     p5, p50, p95   1.5, 3.1, 5.0    1.3, 3.3, 5.3    1.5, 3.2, 5.1
  Triglycerides (mmol/L)       p5, p50, p95   0.6, 1.3, 3.2    0.7, 1.7, 4.2    0.6, 1.4, 3.8
  CRP (mg/L)                   p5, p50, p95   1.0, 3.7, 22.6   0.4, 2.6, 21.7   0.8, 3.3, 22.2
  COHb (%)                     p5, p50, p95   2.1, 3.5, 9.1    0.0, 1.6, 6.2    0.0, 2.9, 8.6
  Leukocytes (10E9/L)          p5, p50, p95   5.1, 7.7, 12.6   5.0, 8.1, 12.7   5.1, 7.8, 12.6

**Notes:** Reference values: creatinine male 75--110, female 65--95; bilirubin \< 17; ALAT \< 45; total cholesterol male 3.9--6.5, female 3.7--6.5; HDL cholesterol \> 1.1; LDL cholesterol \< 4.5; triglycerides 0.5--2; CRP \< 5; COHb nonsmokers \< 2%; smokers \< 5%; toxic \> 15%; leukocytes 4--10.5.

**Abbreviations:** ALAT, alanine aminotransferase; CRP, C-reactive protein; COHb, carboxyhemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein; p5, fifth percentile; p50, median; p95, 95th percentile.
